ライフサイエンスコーパス: adrenergic blocker

1 resence of prazosin (10 mumol/L), an alpha 1-adrenergic blocker.

2 hannah) was previously proposed as a novel B-adrenergic blocker.

3 ents currently or previously treated with a1 adrenergic blockers.

4 giotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxi

5 beta-adrenergic blockers, amiodarone, and sotalol are the mos

6 edications for CVD treatment, including beta-adrenergic blockers and ACE inhibitors, potentially exac

7 amate could be reversibly suppressed by beta-adrenergic blockers and the order of inhibitory potency

8 chieved using calcium-channel blockers, beta-adrenergic blockers, and class I or III antiarrhythmic d

9 oto- and bio-transformations, including beta-adrenergic blockers, antivirals, antibiotics, and pestic

10 beta-adrenergic blockers are still the most common medicine p

11 ors, angiotensin-receptor blockers, and beta-adrenergic blockers, are routinely used and are quite ef

12 e, alpha(2)-adrenergic agonists (AAAs), beta-adrenergic blockers (BABs), carbonic anhydrase inhibitor

13 Initial treatment included a beta-adrenergic blocker (beta-blocker) alone in 24%, a calciu

14 initially thought to be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistently be

15 and in combination with propranolol (a beta-adrenergic blocker), both given systemically, to reduce

16 amine is an FDA approved non-selective alpha-adrenergic blocker, clinically prescribed for oral anest

17 th limitation of sympathoadrenal activation, adrenergic blockers could prevent hypoglycemia-induced a

18 Nonselective beta-adrenergic blockers decrease portal pressure and prevent

19 ental conditions for SERS, we chose the beta-adrenergic blocker drug propranolol as the target analyt

20 , angiotensin-receptor blockers (ARBs), beta-adrenergic blockers, epinephrine, and Kounis syndrome.

21 tients treated with silodosin-a selective a1 adrenergic blocker-for benign prostate hypertrophy (BPH)

22 Propranolol, a pleiotropic B-adrenergic blocker, has been anecdotally reported to red

23 Propranolol, a nonselective beta-adrenergic blocker, has been associated with reduced agi

24 tensin-converting enzyme inhibitors and beta-adrenergic blockers, has been shown to improve the long-

25 n addition, recent studies suggest that beta-adrenergic blockers have a beneficial effect on both sur

26 Thiazide diuretics, niacin, and beta-adrenergic blockers impair glucose homeostasis.

27 Landiolol, a short-acting selective beta1-adrenergic blocker improving the in vivo cardiac perform

28 ar basis for the therapeutic actions of beta-adrenergic blockers in LQT1 and suggest that sodium chan

29 served with propranolol, a nonselective beta-adrenergic blocker, in pretreated animals such that the

30 Additionally, infusion of beta-adrenergic blockers into the amygdala blocks the memory-

31 patients with CHF who are treated with beta-adrenergic blockers is currently unknown.

32 evious reports that betaxolol and other beta-adrenergic blockers may exert its neuroprotective action

33 Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have an additive beneficial effe

34 t-or-flight stress response such as the beta-adrenergic blocker metoprolol and the beta-adrenergic ag

35 Use of antianginal medications (beta-adrenergic blockers, nitrates, and calcium-channel block

36 he effectiveness of betaxolol and other beta-adrenergic blockers on glutamate-induced calcium signals

37 ed by alpha (prazosin)- or beta (propanolol)-adrenergic blockers or L-type Ca2+ channel blockers (ver

38 Carvedilol, a non-selective beta-adrenergic blocker originally designed to treat high blo

39 rged about the effectiveness of the alpha(1)-adrenergic blocker prazosin hydrochloride in the treatme

40 imulation by norepinephrine plus an alpha(1)-adrenergic blocker, prazosin, increased the amplitude of

41 months, 39% of patients were receiving beta-adrenergic blockers (preprocedure proportion, 43%; P < 0

42 , the centrally and peripherally acting beta-adrenergic blocker propranolol (4 or 10 mg/kg ip), or th

43 es were reversed by the addition of the beta-adrenergic blocker propranolol.

44 can be inhibited by the addition of the beta-adrenergic blocker propranolol.

45 greater after the administration of the beta-adrenergic blocker propranolol.

46 rom a mammalian host, we administered a beta-adrenergic blocker, propranolol, to infected mice.

47 In patients with myocardial infarction, beta-adrenergic blockers reduce recurrent myocardial infarcti

48 Prophylactic use of beta-adrenergic blockers reduces the incidence of postoperati

49 ion therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted in greater improvements in

50 Prophylactic treatment with beta-adrenergic blockers should be continued during the pregn

51 0 mg/kg ip), or the peripherally acting beta-adrenergic blocker sotalol (4 or 10 mg/kg ip) immediatel

52 of left ventricular assist devices and beta-adrenergic blockers suggest that attenuation of progress

53 ll as pharmacologic therapy, including alpha-adrenergic blockers (tamsulosin), 5alpha-reductase inhib

54 ropranolol is an approved non-selective beta-adrenergic blocker that is first line therapy for infant

55 Even at high doses, beta-adrenergic blockers, the first-line therapy, often are i

56 Long-term administration of beta-adrenergic blockers to patients after myocardial infarct

57 onic agents, alpha-adrenergic agonists, beta-adrenergic blockers, tricyclic or tetracyclic antidepres

58 entolamine, a reversible, nonselective alpha-adrenergic blocker used in the treatment of hypertensive

59 The beta-adrenergic blocker was only effective when the drug was

60 Treatment with beta-adrenergic blockers was independently associated with a